ProCE Banner Activity

Interim Analysis of Phase III REGENERATE: Obeticholic Acid vs Placebo for NASH

Slideset Download
Obeticholic acid showed significant, dose-dependent improvement in the primary endpoint of fibrosis improvement with no worsening of NASH in this interim analysis of a large randomized trial.

Released: April 16, 2019

Expiration: April 14, 2020

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

AbbVie

Gilead